Jama Oncology最新文献

{"title":"Comment on Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer.","authors":"Yubo Tang, Qingde Wa, Shuai Huang","doi":"10.1001/jamaoncol.2024.4581","DOIUrl":"10.1001/jamaoncol.2024.4581","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1731"},"PeriodicalIF":28.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Errors in Figure 3.","authors":"","doi":"10.1001/jamaoncol.2024.5240","DOIUrl":"10.1001/jamaoncol.2024.5240","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1736"},"PeriodicalIF":28.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11581513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Adding Veliparib to Temozolomide for Patients With MGMT-Methylated Glioblastoma: A Randomized Clinical Trial.","authors":"Jann N Sarkaria, Karla V Ballman, Sani H Kizilbash, Erik P Sulman, Caterina Giannini, Bret B Friday, Nicholas A Butowski, Nimish A Mohile, David E Piccioni, James D Battiste, Jan Drappatz, Jian L Campian, Sandeep Mashru, Kurt A Jaeckle, Barbara J O'Brien, Jesse G Dixon, Brian F Kabat, Nadia L Laack, Leland S Hu, Timothy Kaufmann, Priya Kumthekar, Benjamin M Ellingson, S Keith Anderson, Evanthia Galanis","doi":"10.1001/jamaoncol.2024.4361","DOIUrl":"10.1001/jamaoncol.2024.4361","url":null,"abstract":"<p><strong>Importance: </strong>The prognosis for patients with glioblastoma is poor following standard therapy with surgical resection, radiation, temozolomide, and tumor-treating fields.</p><p><strong>Objectives: </strong>To evaluate the combination of veliparib and temozolomide in glioblastoma based on preclinical data demonstrating significant chemosensitizing effects of the polyadenosine diphosphate-ribose polymerase 1/2 inhibitor veliparib when combined with temozolomide.</p><p><strong>Design, setting, and participants: </strong>Patients with newly diagnosed glioblastoma with MGMT promoter hypermethylation who had completed concomitant radiation and temozolomide were enrolled between December 15, 2014, and December 15, 2018, in this Alliance for Clinical Trials in Oncology trial. The data for this analysis were locked on April 21, 2023.</p><p><strong>Interventions: </strong>Patients were randomized and treated with standard adjuvant temozolomide (150-200 mg/m2 orally, days 1-5) combined with either placebo or veliparib (40 mg orally, twice daily, days 1-7) for 6 cycles.</p><p><strong>Main outcomes and measures: </strong>The primary end point for the phase 3 portion of the trial was overall survival (OS).</p><p><strong>Results: </strong>There were 322 patients randomized during the phase 2 accrual period and an additional 125 patients randomized to complete the phase 3 accrual, for a total of 447 patients in the final phase 3 analysis. The median (range) age for patients was 60 (20-85) years and 190 patients (42.5%) were female. The median OS was 24.8 months (90% CI, 22.6-27.7) for the placebo arm and 28.1 months (90% CI, 24.3-33.3) for the veliparib arm (P = .17). The difference in survival did not meet the prespecified efficacy end point. However, there was a separation of the survival curves that favored the veliparib arm over 24 to 48 months of follow-up. The experimental combination was well tolerated with an acceptable elevation in grade 3 or 4 hematologic toxic effects.</p><p><strong>Conclusions and relevance: </strong>This trial found that adding veliparib to adjuvant temozolomide did not significantly extend OS in patients with newly diagnosed, MGMT-hypermethylated glioblastoma.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov Identifier: NCT02152982.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1637-1644"},"PeriodicalIF":28.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528341/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Factors Associated With Prostate Cancer Among Transgender Women.","authors":"Celeste Manfredi, Antonio Franco, Francesco Ditonno, Eugenio Bologna, Leslie Claire Licari, Costantino Leonardo, Alessandro Antonelli, Cosimo De Nunzio, Edward E Cherullo, Marco De Sio, Riccardo Autorino","doi":"10.1001/jamaoncol.2024.4335","DOIUrl":"10.1001/jamaoncol.2024.4335","url":null,"abstract":"<p><strong>Importance: </strong>Evidence on prostate cancer (PCa) in transgender women is very limited; data are needed to reduce gender disparities in both PCa knowledge and health care.</p><p><strong>Objective: </strong>To evaluate the prevalence of PCa among transgender women in the US and assess the factors associated with PCa, and factors associated with biochemical recurrence (BCR) and bone metastases (BM) secondary to PCa in the transgender population.</p><p><strong>Design, setting, and participants: </strong>A retrospective cohort study was conducted in October 2023, covering the period between 2011 and 2022 (12-year analysis). The study was based on a large, all-payer claims, deidentified, US database (PearlDiver Mariner). Transgender women who were identified as male before assignment of transsexual status codes were included. Patients with PCa were detected in the transgender women population.</p><p><strong>Main outcomes and measures: </strong>PCa diagnosis was selected as primary outcome; BCR and BM were chosen as secondary outcomes.</p><p><strong>Results: </strong>A total of 95 460 transgender women with a mean (SD) age of 52.5 (9.4) years were included. PCa was diagnosed in 589 individuals with a mean (SD) age of 66.8 (10.0) years (estimated prevalence, 0.62%; 95% CI, 0.54%-0.77%). Age (adjusted odds ratio [OR], 1.10; 95% CI, 1.08-1.12; P < .001) and family history (adjusted OR, 2.27; 95% CI, 1.60-4.92; P < .001) were positively associated with PCa in transgender women. Gender-affirming hormone therapy (GAHT) was negatively associated with PCa in transgender women (OR, 0.60; 95% CI, 0.56-0.89; P < .001) but positively associated with BCR (OR, 1.83; 95% CI, 1.21-2.86; P < .001) and BM (OR, 3.96; 95% CI, 1.50-9.99; P < .001) in the transgender population with PCa.</p><p><strong>Conclusions and relevance: </strong>This cohort study found that PCa appeared to be relatively uncommon in transgender women. GAHT may reduce the risk of PCa in transgender patients, but it may also increase the risk of BCR and BM in transgender women with PCa. Further studies are needed to confirm our findings.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1697-1700"},"PeriodicalIF":28.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11450580/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Moving the Needle on Equity in Prostate Cancer.","authors":"Deborah C Marshall","doi":"10.1001/jamaoncol.2024.3927","DOIUrl":"10.1001/jamaoncol.2024.3927","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1700-1701"},"PeriodicalIF":28.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Error in Figure 2.","authors":"","doi":"10.1001/jamaoncol.2024.6231","DOIUrl":"10.1001/jamaoncol.2024.6231","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":"10 12","pages":"1736"},"PeriodicalIF":28.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11659902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142856304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of the Oncology Industrial Complex on Academic Cancer Centers.","authors":"S Gail Eckhardt, Leonidas C Platanias","doi":"10.1001/jamaoncol.2024.4876","DOIUrl":"10.1001/jamaoncol.2024.4876","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1615-1616"},"PeriodicalIF":28.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Survival Outcomes of an Early Intervention Smoking Cessation Treatment After a Cancer Diagnosis.","authors":"Paul M Cinciripini, George Kypriotakis, Janice A Blalock, Maher Karam-Hage, Diane M Beneventi, Jason D Robinson, Jennifer A Minnix, Graham W Warren","doi":"10.1001/jamaoncol.2024.4890","DOIUrl":"10.1001/jamaoncol.2024.4890","url":null,"abstract":"<p><strong>Importance: </strong>Smoking after a cancer diagnosis increases mortality and risk for a second cancer.</p><p><strong>Objective: </strong>To determine the association between time of entry into a smoking cessation intervention following a cancer diagnosis and survival outcomes.</p><p><strong>Design, setting, and participants: </strong>Using a prospective cohort study design, patients with cancer who smoked and received cessation treatment were assessed at 3 months, 6 months, and 9 months following tobacco treatment onset. Survival outcomes of tobacco treatment were measured and compared among patients at the MD Anderson Cancer Center Tobacco Research and Treatment Program. Treatment occurred between January 1, 2006, and March 3, 2022. Patients were excluded if they died before the tobacco treatment ended, received their diagnosis more than 6 months after beginning cessation treatment, or lacked staging information. The data analysis took place from September 2023 to May 2024.</p><p><strong>Interventions: </strong>Cessation treatment consisted of 6 to 8 personalized counseling visits and 10 to 12 weeks of pharmacotherapy. More than 95% of visits were provided via telemedicine.</p><p><strong>Main outcomes and measures: </strong>The primary outcomes were survival as recorded in the MD Anderson Cancer Center tumor registry and 7-day point prevalence abstinence at each follow-up.</p><p><strong>Results: </strong>The main analytical sample consisted of 4526 currently smoking patients diagnosed with cancer and receiving cessation treatment (2254 [49.8%] female; median [IQR] age, 55 [47-62] years). Survival over 15 years increased for those quitting smoking at 3 months (adjusted hazard ratio [aHR], 0.75 [95% CI, 0.67-0.83]), 6 months (aHR, 0.79 [95% CI, 0.71-0.88]), and 9 months (aHR, 0.85 [95% CI, 0.76-0.95]) of follow-up. The optimal survival outcomes were observed for patients who received tobacco treatment within 6 months of a cancer diagnosis. At the 75th percentile, their survival increased from 2.1 years (95% CI, 1.8-2.4 years) among continuing smokers (nonabstainers) vs 3.9 years (95% CI, 3.2-4.6 years) for patients who quit (abstainers). Similar but less pronounced outcomes were noted when tobacco treatment began within 6 months to 5 years following diagnosis, with survival at the 75th percentile of 4.8 years (95% CI, 4.3-5.3 years) for nonabstainers vs 6.0 years (95% CI, 5.1-7.2 years) for abstainers.</p><p><strong>Conclusions and relevance: </strong>The results of this prospective cohort study suggest that evidence-based smoking cessation treatment within 6 months following a cancer diagnosis maximizes survival benefit. This study supports smoking cessation as an important early clinical intervention for patients after being diagnosed with cancer.</p>","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1689-1696"},"PeriodicalIF":28.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11528342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Errors in Figures 2 and 3.","authors":"","doi":"10.1001/jamaoncol.2024.6238","DOIUrl":"10.1001/jamaoncol.2024.6238","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":"10 12","pages":"1736"},"PeriodicalIF":28.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11659908/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142856305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding Clinical Trial Accessibility in the Digital Era With Telemedicine.","authors":"Jiatong Ding, Shuhang Wang, Ning Li","doi":"10.1001/jamaoncol.2024.4908","DOIUrl":"10.1001/jamaoncol.2024.4908","url":null,"abstract":"","PeriodicalId":48661,"journal":{"name":"Jama Oncology","volume":" ","pages":"1734-1735"},"PeriodicalIF":28.4,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142548407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}